Although the 28 immune cell types correlated with both immune-promoting and immune-inhibiting signatures, and they were consistently more highly enriched in immunity-high than in immunity-low gliomas (Fig. 1), we observed higher ratios of immune-promoting/immune-inhibiting signatures (CD8+/CD4+ regulatory T cells and M1/M2 macrophages) in immunity-high than in immunity-low gliomas (two-tailed Student’s t test, P < 0.001) (Fig. 2e). Here, CD8A is linked to central nervous system cancer.